Gene Therapy News and Research

RSS

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery.

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

QIAGEN today announced that it has entered into an agreement with the Institute for Product Quality (ifp), pursuant to which QIAGEN has acquired all rights to 70 molecular food safety tests developed by the Berlin-based specialized laboratory center for food analysis.

From QIAGEN Manchester Limited 26 May 2010

t2c001 product obtains certificate under EMA regulations for ATMPs

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency.

25 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

Amsterdam Molecular Therapeutics a world leader in gene therapy, today reported positive preclinical data from a study using an AAV gene therapy product to lower cholesterol.

21 May 2010

Gene therapy shows positive effects in rat models of PAH: Researchers

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension, according to researchers at the University of Adelaide in Australia.

20 May 2010

GHESKIO awarded prestigious 2010 Gates Award for Global Health

GHESKIO, an institution in Haiti founded nearly three decades ago to fight a mysterious killer disease later identified as AIDS, has been awarded the prestigious 2010 Gates Award for Global Health for its years of groundbreaking clinical service, research and training to effectively treat and prevent the spread of the HIV/AIDS and other related illnesses.

19 May 2010

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis."

19 May 2010

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.

18 May 2010

Senesco Technologies third-quarter net loss increases to $5.28M

Senesco Technologies, Inc. today announced financial results for the three and nine months ended March 31, 2010.

18 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Neurologix reports lower net loss of $3.5M for first-quarter 2010

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2010.

14 May 2010

CEVEC, Aragen Bioscience announce strategic license agreement

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California based contract research and development organization, announced today the signing of a strategic license agreement. This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.

12 May 2010

Unotron keyboards prevent sample contamination, germ spread at UNC Gene Therapy Center

The Gene Therapy Center at the University of North Carolina (UNC) asserts that Unotron's ruggedly designed, airtight SpillSeal® technology offers an optimal solution for use where a sterile environment is critical. Unotron, creator of hermetically-sealed, dishwasher safe, medical grade washable computer keyboards, scroll wheel mice, and smartcard readers, announced today that its keyboards provided to the UNC Gene Therapy Center offer an optimal solution for preventing contamination to samples and the spread of the germs.

11 May 2010

Potential new drug therapies for treatment of tuberculosis

Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.

11 May 2010

Cryo-EM images shed light on virus structure, function

UCLA researchers report in the April 30 edition of the journal Cell that they have imaged a virus structure at a resolution high enough to effectively "see" atoms, the first published instance of imaging biological complexes at such a resolution.

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Particle Sciences extends collaboration with Microfluidics to implement MRT system

Particle Sciences and Microfluidics extended their collaboration with the placement of the newly-announced Microfluidics Reaction Technology system at Particle Sciences.

5 May 2010

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.

5 May 2010

Gene Therapy News and Research

Further Reading

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

t2c001 product obtains certificate under EMA regulations for ATMPs

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

New therapy program serves as foundation for ongoing clinical development

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

Gene therapy shows positive effects in rat models of PAH: Researchers

GHESKIO awarded prestigious 2010 Gates Award for Global Health

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies third-quarter net loss increases to $5.28M

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Neurologix reports lower net loss of $3.5M for first-quarter 2010

CEVEC, Aragen Bioscience announce strategic license agreement

Unotron keyboards prevent sample contamination, germ spread at UNC Gene Therapy Center

Potential new drug therapies for treatment of tuberculosis

Cryo-EM images shed light on virus structure, function

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Particle Sciences extends collaboration with Microfluidics to implement MRT system

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

Event guide: 9th Gene Therapy Development Summit 2026 eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News